Gilder Gagnon Howe & Co. LLC purchased a new stake in Aldeyra Therapeutics, Inc (NASDAQ:ALDX) in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 218,081 shares of the biotechnology company’s stock, valued at approximately $3,010,000. Gilder Gagnon Howe & Co. LLC owned 1.04% of Aldeyra Therapeutics as of its most recent SEC filing.
Several other institutional investors also recently added to or reduced their stakes in the company. Northern Trust Corp boosted its holdings in Aldeyra Therapeutics by 297.2% during the second quarter. Northern Trust Corp now owns 191,275 shares of the biotechnology company’s stock worth $1,520,000 after purchasing an additional 143,124 shares during the last quarter. Bank of New York Mellon Corp boosted its holdings in Aldeyra Therapeutics by 139.7% during the second quarter. Bank of New York Mellon Corp now owns 49,842 shares of the biotechnology company’s stock worth $396,000 after purchasing an additional 29,051 shares during the last quarter. BlackRock Inc. boosted its holdings in Aldeyra Therapeutics by 1,881.2% during the second quarter. BlackRock Inc. now owns 780,744 shares of the biotechnology company’s stock worth $6,207,000 after purchasing an additional 741,337 shares during the last quarter. Stanley Laman Group Ltd. boosted its holdings in Aldeyra Therapeutics by 54.4% during the second quarter. Stanley Laman Group Ltd. now owns 98,892 shares of the biotechnology company’s stock worth $786,000 after purchasing an additional 34,863 shares during the last quarter. Finally, Schwab Charles Investment Management Inc. acquired a new position in Aldeyra Therapeutics during the second quarter worth $237,000. Institutional investors own 57.90% of the company’s stock.
NASDAQ ALDX opened at $11.00 on Friday. The company has a current ratio of 8.11, a quick ratio of 8.11 and a debt-to-equity ratio of 0.03. Aldeyra Therapeutics, Inc has a 1 year low of $5.55 and a 1 year high of $16.70.
Aldeyra Therapeutics (NASDAQ:ALDX) last posted its quarterly earnings results on Thursday, August 9th. The biotechnology company reported ($0.46) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.43) by ($0.03). Equities analysts expect that Aldeyra Therapeutics, Inc will post -1.77 earnings per share for the current fiscal year.
Several research analysts recently commented on ALDX shares. Cantor Fitzgerald set a $30.00 target price on shares of Aldeyra Therapeutics and gave the stock a “buy” rating in a report on Thursday, October 4th. ValuEngine raised shares of Aldeyra Therapeutics from a “hold” rating to a “buy” rating in a research report on Thursday, September 20th. Stifel Nicolaus upped their price target on shares of Aldeyra Therapeutics from $16.00 to $36.00 and gave the stock an “in-line” rating in a research report on Wednesday, September 26th. They noted that the move was a valuation call. Zacks Investment Research lowered shares of Aldeyra Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, August 14th. Finally, Janney Montgomery Scott initiated coverage on shares of Aldeyra Therapeutics in a research report on Thursday, September 13th. They set a “buy” rating on the stock. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and five have issued a buy rating to the company. The stock currently has an average rating of “Buy” and an average price target of $24.92.
Aldeyra Therapeutics Company Profile
Aldeyra Therapeutics, Inc, a biotechnology company, focuses on the development of products for inflammation, inborn errors of metabolism, and other diseases in the United States and internationally. It is developing ADX-102, a small molecule designed to trap and allow for the degradation of aldehydes, as well as ADX-103 and ADX-104 novel candidates for the treatment of noninfectious anterior uveitis, allergic conjunctivitis, dry eye syndrome, sjögren-larsson syndrome, and succinic semi-aldehyde dehydrogenase deficiency.
Read More: How Do You Make Money With Penny Stocks?
Want to see what other hedge funds are holding ALDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aldeyra Therapeutics, Inc (NASDAQ:ALDX).
Receive News & Ratings for Aldeyra Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aldeyra Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.